Company intelligence / Profile preview

Riffyn

Oakland, California, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Riffyn is not a therapeutic developer and has no clinical pipeline; it provides SaaS informatics platforms used by biopharma and biotech companies to design, track and analyze R&D and manufacturing processes, including in FDA‑regulated GxP settings[1][2][3].

Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

BASF (white biotechnology and fermentation R&D digitalization using Riffyn SDE)[1]Novozymes (multi‑year digital transformation and data analytics partnership, Riffyn as cornerstone of R&D data architecture)[1]Multiple top global biopharmaceutical and biotechnology companies (Riffyn reports supporting eight of the top 15 global firms)[1][2]Waters Corporation (strategic investor and commercial collaborator around analytics/measurement customers)[2]M Ventures (Merck KGaA corporate VC, strategic investor)[2]

Beyond the preview

Go deeper on Riffyn.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Riffyn.

Explore the full profile